Co-financing by the EIC Fund to ramp up women's health solution to POP MISGAV, Israel, June 30, 2025 /PRNewswire/ -- Escala Medical Ltd. ("Escala"), a medical technology company specializing in innovative repair solutions for women with Pelvic Organ Prolapse (POP), today announced the successful completion of a $4.5 million funding round. The investment included the EIC Fund, following a €2.5 million grant awarded to Escala in October 2023 through the prestigious EIC Accelerator program. The rou

Novel disposable sensor pad and software offers a simple, universal, and cost-effective solution for managing respiratory motion in image-guided radiation therapy MINNEAPOLIS, June 30, 2025 /PRNewswire/ -- EmpNia™, a medical device innovator dedicated to improving precision in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance to market its breakthrough product, eMotus™, to hospitals and cancer centers throughout the United States. Managing

RICHMOND, Va., June 30, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) will be added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. market opens today as part of the 2025 Russell indexes reconstitution. The annual reconstitution of the Russell U.S. indexes captures the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in

SHANGHAI, China and SOUTH SAN FRANCISCO, CA, USA I June 26, 2025 I Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH), an innovative biopharmaceutical company, and Calico Life Sciences LLC (Calico) a biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D. Levinson, Ph.D., today announced an exclusive licensing agreement for IL-11 directed therapeutics, including 9MW3811, a Phase I monoclonal antibody (mAb). Preclinically, Mabwell has explo

ALLSCHWIL, Switzerland I June 30, 2025 I Idorsia Ltd. (SIX: IDIA) today announced a milestone in the development of its first bacterial vaccine based on the company’s synthetic glycan chemistry platform. The Clostridioides difficile (C. dfficile) vaccine is based on a synthetic glycan mimicking a surface glycan antigen and covers more than 90% of all existing strains of C. difficile bacteria and also targets the spores. Initial data showed that the vaccine is well-tolerated and showed immunogeni

Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx’s collaborative discovery model AMSTERDAM, The Netherlands I June 30, 2025 I argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people su

SAN FRANCISCO, CA, USA and SUZHOU, China I June 30, 2025 I Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, held its Oncology R&D Day, unveiling its forward-looking strategy centered on dual innovation in next-generation immuno-oncology (IO) and antibody-drug conjugate (

Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency of each site. Both facilities undergoing expansions are essential components of Piramal Pharma's integrated antibody-drug conjugate (ADC) offering, ADCelerate™, reflecting the company's commitment to delivering innovative solutions that align with patient needs. Piramal Pharma celebrated the groundbreaking

Caprelsa® (vandetanib) is a medicine that is used in adults and children above 5 years of age to treat aggressive and symptomatic medullary thyroid cancer1. This is a new step forward in ESTEVE's international growth journey focused on highly specialized treatments for high unmet medical and patient needs.  BARCELONA, Spain, June 30, 2025 /PRNewswire/ -- ESTEVE has entered into an agreement with Sanofi to acquire Caprelsa® (vandetanib) rights in more than 50 countries, a treatment that is used i

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlifidase, at the 2025 International Transplant Congress of the European Society for Organ Transplantation (ESOT), taking place in London, June 29 – July 2.